

Newsletter

Volume 1, Winter Issue, 2014



Canadian Stroke Prevention
Intervention Network

Reseau Canadien pour la Prevention
des Accidents Cerebrovasculaires

C-SPIN Upcoming Events

1st Annual Clinical Trials Workshop

January 21st—23rd, 2015

Fairmount Chateau Laurier

Ottawa, Ontario



Inside this issue:

C-SPIN Upcoming Events	p1
Updates on the C-SPIN Pilot Grant Application	p1
ARTESiA Press Release	p2
C-SPIN Study Updates	p2
C-SPIN Contact Information	p2

This is an exciting program and a valuable educational opportunity which includes formal training on clinical trial design, best practice of conducting clinical trials, statistical methods, knowledge translation skills and finally trainees will draft and defend a prepared research proposal.

11 successful candidates selected from a pool of 25 applicants will participate in the workshop.

The trainees will learn from the experts about research in clinical trials, hear about novel concepts in atrial fibrillation and stroke from leaders in the field and work with outstanding mentors to help guide the next generation of Canadian researchers.

Learn from the expert about research in clinical trials.

Hear about novel concepts in atrial fibrillation and stroke from leaders in the field.

Work with outstanding mentors to help guide your career.

Updates on the C-SPIN Pilot Grants Call for Applications

* Eligibility:

- Principal Applicants should have a full-time appointment in a Canadian University.
- Principal Applicants who are invited to the on-line full application phase must become C-SPIN members prior to submission of the full proposal.
- Projects should fulfill ALL of the C-SPIN relevancy criteria:
 1. Randomized controlled trials; or other clinical studies which would form the basis of future randomized trials.
 2. Must be related to atrial fibrillation, related arrhythmia or their predisposing conditions.
 3. Must be related to stroke prevention.

* Application Process:

LOI Phase

19 applications received, most applicants are junior investigators. All applications will be reviewed and evaluated by a panel of three C-SPIN Executive Committee Members.

Application Phase

Successful candidates will be notified via e-mail by February 15th, and will be instructed to proceed to the full application phase. The full application and required attachments should be submitted on [C-SPIN Website](#). (Ctrl+Click)

C-SPIN Pilot Grant Application Deadlines:

15th Dec 2014 -	LOI submission
15th Feb 2015 -	Full Application submission for successful LOIs
15th April 2015 -	Results Announcement
1st May 2015 -	Awards Commencement





Happy Holidays



Joyeuses Fêtes!

Study Updates

Study Title	Study Progression Status	Number of Sites	Number of Patients Enrolled
ARTESiA	Planning / Start-Up	Target: 100 Enrolled: 67 Activated: 0	Target: 4000 Enrolled: 0 Projected PPFV: February 2015
BRAIN – AF	Planning / Start-Up	Target: 100	Target: 500 for the pilot phase Projected PPFV: January 2015
ESCAPE	Follow-Up 90 day follow-up	Target: 25 Enrolled: 22 Activated: 23	Target: 500 Enrolled: 316
ESUS Global Survey & Registry	Close-Out	Target: 20 Enrolled: 19	Target: 2000 Enrolled: 2145
LAAOS III	Enrolment & Follow-Up	Target: 100 Enrolled: 71 Activated: 24	Target: 4,700 Enrolled: 571
OCEAN	Planning / Start-Up	Target: 35 Enrolled: 30 Activated: 0	Target: 1400 Enrolled: 0
ASSERT III	Enrolment	Target: 8 Enrolled: 8 Activated: 8	Target: 150 Enrolled: 110
PIAAF - Pharmacy	Enrolment	Target: 20 Enrolled: 20 Activated: 20	Target: 2000 Enrolled: 462
PIAAF - FP	Planning / Start-Up	Target: 30 Enrolled: 15 Activated: 0	Target: 2,950 Enrolled: 0 Projected PPFV: February 2015
PIAAF - Home	Planning / Start-Up	Target: 30 Enrolled: 0	Target: 822 Enrolled: 0 Projected PPFV: January 2015
C-CUSP (ED)	Planning / Start-Up	Target: 3 Enrolled: 3 Activated: 0	Target: 360 Enrolled: 0 Projected PPFV: February 2015



Set To Launch In Early 2015

The ARTESiA study will evaluate the efficacy of apixaban for the prevention of stroke or systemic embolism in patients with device detected sub-clinical atrial fibrillation. This randomized clinical trial will include 4000 patients from at least 100 sites globally and will be the first trial to definitively evaluate whether patients with sub-clinical atrial fibrillation benefit from oral anticoagulation.

Site Start-up activities are now underway in Canada, USA, Austria, Denmark, France, Germany, Italy, Netherlands, Norway, Switzerland and UK. Plans are also in motion to add sites in Belgium, Hungary and Sweden. Estimated first patient enrolled by February 2015 with anticipated study completion in spring of 2019.

“ARTESiA is a very important clinical trial because sub-clinical or silent atrial fibrillation is not only a risk factor for stroke in patients with pacemakers or defibrillators but is likely common in the general population of elderly patients.

The results of ARTESiA may not only answer a practical question regarding management of stroke risk in pacemaker and defibrillator patients, but is expected to also help define the role of screening for atrial fibrillation in the general population.”

~ Dr. Jeff Healey, Principal Investigator



The Coordination Office

Location:

Population Health Research Institute
David Braley Research Institute;
20 Copeland St,
Hamilton, Ontario

Mailing Address:

C-SPIN
Hamilton General Hospital
David Braley Research Institute
237 Barton Street East,
Hamilton, Ontario.
L8L 2X2

Email: cspin@phri.ca Web: www.cspin.ca